201 related articles for article (PubMed ID: 29478347)
21. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.
Raut SK; Kulkarni PS; Phadke MA; Jadhav SS; Kapre SV; Dhere RM; Dhorje SP; Godse SR
Clin Vaccine Immunol; 2007 Oct; 14(10):1370-1. PubMed ID: 17699834
[TBL] [Abstract][Full Text] [Related]
22. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
Kraszewska-Głomba B; Matkowska-Kocjan A; Miśkiewicz K; Szymańska-Toczek Z; Wójcik M; Banyś D; Szenborn L
Vaccine; 2016 Nov; 34(48):5903-5906. PubMed ID: 27997341
[TBL] [Abstract][Full Text] [Related]
23. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
[TBL] [Abstract][Full Text] [Related]
24. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
[TBL] [Abstract][Full Text] [Related]
25. Successes and challenges for preventing measles, mumps and rubella by vaccination.
Bankamp B; Hickman C; Icenogle JP; Rota PA
Curr Opin Virol; 2019 Feb; 34():110-116. PubMed ID: 30852425
[TBL] [Abstract][Full Text] [Related]
26. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E
Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
30. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
31. Differential durability of immune responses to measles and mumps following MMR vaccination.
Kennedy RB; Ovsyannikova IG; Thomas A; Larrabee BR; Rubin S; Poland GA
Vaccine; 2019 Mar; 37(13):1775-1784. PubMed ID: 30797639
[TBL] [Abstract][Full Text] [Related]
32. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
33. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
[TBL] [Abstract][Full Text] [Related]
34. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.
Rasheed MAU; Hickman CJ; McGrew M; Sowers SB; Mercader S; Hopkins A; Grimes V; Yu T; Wrammert J; Mulligan MJ; Bellini WJ; Rota PA; Orenstein WA; Ahmed R; Edupuganti S
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19071-19076. PubMed ID: 31481612
[TBL] [Abstract][Full Text] [Related]
35. Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program.
Ngaovithunvong V; Wanlapakorn N; Tesapirat L; Suratannon N; Poovorawan Y
J Infect Dev Ctries; 2016 Aug; 10(7):735-40. PubMed ID: 27482805
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control.
Cardemil CV; Dahl RM; James L; Wannemuehler K; Gary HE; Shah M; Marin M; Riley J; Feikin DR; Patel M; Quinlisk P
N Engl J Med; 2017 Sep; 377(10):947-956. PubMed ID: 28877026
[TBL] [Abstract][Full Text] [Related]
37. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
[TBL] [Abstract][Full Text] [Related]
39. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders.
Gentile I; Bravaccio C; Bonavolta R; Zappulo E; Scarica S; Riccio MP; Settimi A; Portella G; Pascotto A; Borgia G
In Vivo; 2013; 27(3):377-82. PubMed ID: 23606694
[TBL] [Abstract][Full Text] [Related]
40. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
